Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Arch Biopartners Inc V.ARCH

Alternate Symbol(s):  ACHFF

Technology Scientific & Technical Instruments
Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is... see more

Bullboard (TSXV:ARCH)

View:
Prev 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 ... Next
Post by PeptidePeteon Sep 23, 2024 1:02pm

Dosing of Key Inflammation pathway marked 200 days

Learn more about LSALT Peptide and those who developed it here.
66
Comment by Viking2233on Sep 22, 2024 1:47pm

RE:Cilastatin, new therapeutic promise for acute kidney injury

Great post Pete, just need to get the Pontiac trial approved at various levels and started!
83
Discussion
Post by PeptidePeteon Sep 21, 2024 1:44pm

Cilastatin, new therapeutic promise for acute kidney injury

Cilastatin, a New Therapeutic Promise for Acute Kidney Injury
88
Discussion
Post by PeptidePeteon Sep 17, 2024 8:34pm

Why do Phase II trials fail?

Failures in phase II testing overall usually occur because: 1) previously unknown toxic side effects occur (50%); 2) the trials show insufficient efficacy to treat the medical condition being tested ...more  
143
Post by PeptidePeteon Sep 12, 2024 3:55pm

Expanding Phase II AKI Trial - Alberta Dosing Approved

University of Calgary Cumming School of Medicine Approved by AHS
71
Post by Betteryear2on Sep 11, 2024 9:00am

Alberta Health Services Approval to Proceed

TORONTO, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that Alberta Health Services (AHS) has approved ...more  
77
Post by Viking2233on Sep 08, 2024 5:06pm

Thankfully we have Turkey

Calgary site was announced 26 weeks ago, yes you read that correctly, 6 months ago! We still have yet to obtain the final approval so we can dose patients. The same goes for the two Toronto sites ...more  
199
Post by Viking2233on Aug 20, 2024 9:43am

Kidney Foundation of Canada

I was searching the web regarding University of Calgary trying to find information on the recently announced Pontiac trial to try and get a handle on dates and applications but no such luck. I did ...more  
227
Post by Viking2233on Aug 19, 2024 9:30am

Canadian Clinical Site Approvals too Long

Here is another article below on the approval process for clinical trials done in Canada. The approval process takes 6-12 months. We announced our Canadian sites in March & April 2024 so we ...more  
181
Post by Viking2233on Aug 18, 2024 7:14pm

Interesting article

The article below might support my theory regarding Canadian sites obtaining final approvals to participate in our phase 2 AKI trial. All I can say is we should be thankful we are doing in Turkey ...more  
202
Post by Viking2233on Aug 15, 2024 9:23am

Canadian Sites

What are your thoughts on the 3 Canadian sites (Calgary & Toronto) participating in our AKI Phase 2 trial. I was looking back on news releases. Calgary site was announced in March 2023 and ...more  
277
Comment by Cb27743on Aug 10, 2024 12:33pm

RE:Communication

lol pulling up a post from 2 years ago. How many did you post just this last month?
48
Discussion
Post by Viking2233on Aug 10, 2024 8:30am

Communication

CB, I took the time to review your posting history and it appears you also feel communication is not managements strong suit. Below are few of your rants: Comment by Cb27743on Dec 01 ...more  
209
Discussion
Prev 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 ... Next
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities